<?xml version="1.0" encoding="UTF-8"?>
<p id="para20">By the 1930s, serum therapy was widely used to treat a range of infectious diseases, such as scarlet fever and pneumococcal pneumonia; however, its use had declined by the middle of the 20th century as a result of the development of antimicrobials. The interest in passive antibody therapy has been renewed periodically, especially when new epidemics or pandemics emerge, including previous coronavirus outbreaks—SARS in 2002–04 and Middle East respiratory syndrome in 2012. Promise was shown for SARS, with a 
 <ext-link ext-link-type="uri" xlink:href="https://link.springer.com/article/10.1007/s10096-004-1271-9" id="interrefs10" xmlns:xlink="http://www.w3.org/1999/xlink">2004 study done in Hong Kong</ext-link> showing earlier discharge from hospital and lower mortality in patients given convalescent plasma earlier than those who were given it later. For other infectious diseases, positive results led the 
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/" id="interrefs20" xmlns:xlink="http://www.w3.org/1999/xlink">WHO to publish guidance</ext-link> on the use of the treatment for Ebola virus disease, and treatment benefits have been shown in terms of lower morality in patients with 
 <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21248066/" id="interrefs30" xmlns:xlink="http://www.w3.org/1999/xlink">pandemic 2009 influenza A H1N1 virus infection</ext-link>. However, definitive clinical evidence showing the efficacy of convalescent plasma is scarce.
</p>
